Gene expression test identifies prostate cancer patients who benefit from hormone therapy

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery – the first predictive biomarker in this setting.